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Background/aim: The relationship between the activation of the renin-angiotensin system and the increase in erythropoiesis has been
shown in many studies. In addition, the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers
(ARB) has been reported to reduce hemoglobin levels in various patient groups at risk for secondary erythrocytosis/polycythemia. The
aim of our study is to investigate whether there is a change in hemoglobin levels after starting ACEIs or ARBs in patients who have not
used them before.
Materials and methods: Three hundred and fifty-one patients who were started on renin angiotensin aldosterone system (RAAS)
blockers were evaluated retrospectively. None of the patients had anemia before starting RAAS blockers. A median of 6 (4–12) months
after the start of the drug, complete blood count and kidney function tests were evaluated. Hemoglobin values before and after the start
of the drug were compared statistically.
Results: A statistically significant decrease in mean Hb value was found after starting ACEIs or ARBs (14.39 ± 1.29 g/dL vs 13.98 ± 1.36
g/dL, p < 0.001). The decrease in control Hb values was higher in the ARB group than in the ACEI group (–0.53 ± 0.06 g/dL vs –0.29 ±
0.06 g/dL, p < 0.001).
Conclusion: A significant decrease in mean Hb level was detected in the first year following the first administration of ACEIs or ARBs.
Key words: Anemia, hypertension, renin, angiotensin, aldosterone

1. Introduction
Activation of the renin angiotensin aldosterone system
(RAAS) is central to many common pathological
conditions such as hypertension, heart failure, and kidney
disease. RAAS blockers, which were intended for the
treatment of hypertension when they were first used,
have since become the first choice in the treatment of
hypertension; and independent of their blood pressure
lowering effect, RAAS blockers are widely used because
of their kidney-protective and heart-protective effects. [1].
Several studies have found that RAAS activation can
increase erythropoiesis and be associated with secondary
erythrocytosis [2,3]. It has also been reported in the
literature that the use of angiotensin converting enzyme
inhibitors (ACEIs) or angiotensin receptor blockers

(ARBs) reduces hemoglobin (Hb) levels in various patient
groups at risk for secondary erythrocytosis/polycythemia
[4–6]. In experimental studies, RAAS blockade has been
shown to reduce hemoglobin and hematocrit levels
[7,8]. The exact mechanism is not fully understood, but
angiotensin II may be responsible for erythropoietin
secretion or direct stimulation of erythroid progenitors
[9,10]. In clinical studies, there are conflicting results as to
whether RAAS blockers reduce hemoglobin levels [11,12].
There are studies in the literature reporting that ACEIs
have a reducing effect on Hb levels and ARBs have a more
limited effect [13], as well as other studies reporting the
opposite [14].
The aim of this study is to investigate whether there is a
change in Hb levels after starting ACEI or ARB treatment
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in patients with an estimated glomerular filtration rate
(eGFR) ≥30 mL/min and who have not used ACEIs or
ARBs before.
2. Materials and methods
Adult patients admitted to the nephrology and internal
medicine outpatient clinics of the University of Health
Sciences-Keçiören Educational and Research Hospital
between 01/07/2017 and 01/07/2019 and newly started to
use ACEI or ARB group drugs due to diabetic nephropathy
or hypertension were included in this retrospective
study. Patients with anemia, iron deficiency, vitamin B12
deficiency, folate deficiency, those who were treated for
anemia in the last 6 months, and those who had a history
of blood transfusion or a history of blood donation in the
last 1 year were excluded from the study. Patients who
had eGFR less than 30 mL/min/1.73 m², those who had
a history of active infection or malignancy, and those
who had an operation or any condition that causes active
bleeding during study period were also excluded from the
study.
The study protocol was approved by the ethics
committee of the Keçiören Education and Research
Hospital.
Patients’ demographic properties (age, sex, history of
diabetes mellitus, history of hypertension, name and group
of the newly started antihypertensive drug) were obtained
from their medical records. Patients’ laboratory data such
as hemogram, serum creatinine, and eGFR levels evaluated
before RAAS blockers initiation and at least 3 months after
initiation were also obtained from the medical records.
The estimated glomerular filtration rate was calculated
by 4-variable MDRD equation described by the National
Kidney Foundation as follows: GFR (mL/min/1.73 m2)
= 175 × (Scr)⁻ -1.154 × (Age)⁻-0.203 × (0.742 if female)
× (1.212 if African American) [15]. Anemia was defined
according to WHO criteria that Hb level is below 12 g/dL
for women and 13g/dL for men [16].
Data analysis was performed using SPSS version
15.0 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was
considered statistically significant. The Kolmogorov–
Smirnov test was used to asses the normality of variables.
All continous data showed nonnormal distribution.
Results were expressed as median (min–max) for
continous variables and as numbers and percent for
categorical variables. Chi-square test, Fisher’s exact test,
Mann–Whitney U test, and unpaired Student’s t-test were
used for the comparison of findings in two groups. The
values before and after the RAAS began were compared by
paired Student’s t-test.
3. Results
Three hundred and fifty-one patients were included in
the study. The number of patients who started ACEIs and

3048

ARBs was 178 and 173, respectively. A complete blood
count and kidney function tests were evaluated on average
6 (4–12) months after the start of the drug. The most
commonly used ACEIs and ARBs among patients were
perindopril (39.8%) and candesartan (48.3%), respectively.
Demographic and clinical characteristics of the patients
are given in Table 1.
As shown in Table 1, many of the clinical and laboratory
characteristics of patients using ACEI and ARB were
similar. The percentage of diabetes was higher in the ACEI
group (37.6 % vs 20.2%, p < 0.001). It was found that the
control blood count was evaluated later after starting the
drug in the ARB group than in the ACEI group (7 (4–12)
months vs 5 (4–12) months, p < 0.05).
The initial mean Hb value of patients before the drug
was started was 14.39 ± 1.29 g/dL. A statistically significant
decrease in mean Hb value was found after starting ACEI
or ARB (13.98 ± 1.36 g/dL, p < 0.001).
Delta_Hb value (Delta_Hb=control Hb-initial Hb) was
obtained by calculating the difference between initial Hb
and control Hb. Delta_eGFR (Delta_eGFR=control eGFRinitial eGFR) was obtained by calculating the difference
between control eGFR and initial eGFR. It was found that
the decrease in control Hb values was greater in the ARBgroup than in the ACEI-group (Table 2). There were no
significant differences in eGFR changes between the two
study groups (Table 2).
4. Discussion
In this study, a significant decrease in mean Hb levels was
observed in the follow-up of patients who were started on
ACEI or ARB. In addition, it was found that the decrease
in Hb levels of the patients who were started on ARB was
higher than that in the patients who were started on ACEI.
Most of the patients included in the study had no renal
dysfunction (eGFR ≥ 60 mL/min). However, in a small
number of patients with mild renal dysfunction (eGFR
30–60 mL/min), the decrease in mean Hb levels after
starting ACEI or ARB was similar to the decrease in mean
Hb levels in patients with eGFR ≥ 60 mL/min.
The effects of RAAS on hematopoiesis are observed both
during the formation and proliferation of hematopoietic
cells in the bone marrow during the embryological
period and during the synthesis of erythropoietin and the
effect of erythropoietin on target cells. The effect of local
RAAS on hematopoietic progenitor cells is thought to be
mediated by AT-1 receptors [17,18]. In a study on mice,
it was shown that AT-2 deficiency causes anemia, and Hb
and hematocrit levels increase with AT-2 infusion [19]. In
addition, it was shown that the burst-forming unit (BFU)
and colony-forming unit (CFU) levels have increased
with the addition of AT-2 to the in vitro culture of human
peripheral blood mononuclear cells or bone marrow cells
[10,19].
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Table 1. Comparison of demographic and laboratory characteristics of patients using ACEIs or ARBs.
Number

351

ACEI-group (178)

ARB-group (173)

p

Sex (F) (%)

55.6

50.8

49.2

0.981*

Age (years)

56 (19–87)

54 (19–87)

56 (25–79)

0.334**

Diabetes mellitus (%)

26.2

37.6

20.2

0.001*

Hypertension (%)

97.4

94.8

100

0.012*

Follow-up period (months)

6 (4–12)

5 (4–12)

7 (4–12)

0.013**

Hb (g/dL)

14.4 (12.0–16.7)

14.5 (12.0–16.3)

14.3 (12.0–16.7)

0.615**

Htc(%)

43.0 (35.0–53.6)

43.0 (35.0–52.3)

42.0 (36.0–53.6)

0.650**

MCV(fL)

88 (80–100)

88 (82–100)

86 (80–100)

0.776**

RBC(x10⁶⁄µL)

4800 (4200–5600)

4800 (3700–5500)

4700 (3900–5600)

0.939**

Ferritin(ng/mL)

65 (27–277)

47 (28–277)

53 (27–114)

0.626**

Vitamin B12(pg/mL)

323 (198–647)

374 (201–631)

325 (198–647)

0.320**

Folate (ng/mL)

7 (5–17)

7 (5–17)

7 (5–16)

0.530**

Transferrin saturation (%)

36 (20–70)

40 (20–60)

40 (20–70)

0.926**

eGFR (mL/min/1.73 m²)
eGFR 30–60 (%)
eGFR ≥ 60 (%)

93 (32–127)
7.7
92.3

93 (34–117)

93 (32–127)

0.988**

Serum creatinine (mg/dL)

0.78 (0.30–1.80)

0.77 (0.3–1.80)

0.80 (0.40–1.70)

0.753**

ACEI: Angiotensinogen converting enzyme inhibitors, ARB: Angiotensin receptor blockers, eGFR: Estimated glomerular filtration rate.
* Chi-square test, ** Mann–Whitney U test
Table 2. Delta_Hb and Delta_eGFR values in study groups.
ACEI-group
(N:178)
Delta_Hb
Delta_eGFR

–0.29 ± 0.06
–3.2 ± 0.80

ARB-group
(N:173)
–0.53 ± 0.06

–1.8 ± 0.77

p*

0.001
0.403

ACEI: Angiotensinogen converting enzyme inhibitors, ARB:
Angiotensin receptor blockers, eGFR: Estimated glomerular
filtration rate.
*Unpaired Student’s t-test

AT-2 has been shown to be associated with
erythropoietin production from peritubular fibroblasts of
the kidney in vitro [9]. However, there are uncertainties
about the relationship between ACE inhibition and
erythropoietin levels in vivo. It has been reported in
some studies that ACEI administration reduces plasma
erythropoietin levels or induces erythropoietin resistance
[20,21]. In a study conducted in 10 healthy volunteers in
1992, the possibility of reducing plasma EPO concentrations

of enalapril and captopril as ACEIs was investigated. A
significant decrease was found in the mean plasma EPO
concentration measured after 28 days of treatment with
both ACE inhibitors [22]. In addition, when an ACEI,
enalapril, was given to hypertensive patients with chronic
nephropathy, it was reported in the follow-up after 90 days
that the mean Hb value decreased by about 1 g/dL, and
EPO levels decreased from 32 U/L to 24 U/L [23]. ACE
inhibitors are thought to reduce the formation of EPO
by inhibiting the production of angiotensin-II [21,23].
In addition, anemia due to ACEIs and ARBs has been
associated with decreased erythropoietin production as a
result of increased renal plasma flow and increased oxygen
delivery [23]. ACEIs have also been shown to reduce
insulin-like growth factor levels. Insulin-like growth
factor plays a role in stimulating the erythroid sequence
and inhibiting the catabolism of N-acetyl-seryl-aspartylproline, a natural peptide that reduces the proliferation of
red cell precursor cells [24].
A study of kidney transplant patients concluded
that the ACEI-related reduction in Hb levels may reflect
modulation of multiple factors interacting with erythroid
bone marrow precursors [25]. In parallel, it was reported
in an experimental study that losartan, an AT-II type 1
receptor (AT-1) antagonist, developed posttransplant
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erythrocytosis without altering serum erythropoietin
levels [10]. Angiotensin 2 increases the proliferation
of early erythroid progenitors, while ARB completely
abolishes this effect [10].
Administration of captopril in hemodialysis patients
may contribute to worsening of anemia [26]. In addition,
it has been shown that the use of ACEI/ARB in patients
with end-stage renal disease who need erythropoiesis
stimulating agents (ESA) causes ESA resistance and
increases the dose of ESA that should be used to correct
anemia. [27]. Similarly, both ACEIs and ARBs have been
reported to cause ESA resistance in peritoneal dialysis
patients [14].
Clinical studies have also investigated the association of
RAAS blockers with anemia in patients without significant
chronic kidney disease. A retrospective cohort study
examined Hb values before and 1 year after initiation of
medication in all adults receiving ACEIs, ARBs, or calcium
channel blockers. Treatment with ACEIs and ARBs has
been found to be associated with a higher risk of anemia
and reduced Hb levels. A similar association has not been
observed in patients using calcium channel blockers
[28]. Another retrospective study investigated whether
patients with hypertension, diabetes, or ischemic heart
disease had a decrease in Hb levels on average 1 year after
initiation of ACEI or ARB. It has been reported that the
use of ACEIs is associated with a decrease in Hb levels,
and no similar association was found with the use of ARBs
[8]. In contrast to that study, Inoue et al. [14] reported a
significant decrease in Hb value with ARB use, but this
effect was not observed with ACEI in diabetic patients
with chronic kidney disease. In our study, a decrease in
Hb levels was detected in patients who started both ACEI
and ARB, which were evaluated at least 3 months after
the start of the drug. However, this decrease in Hb value
is more pronounced in ARB users. In our study, there
were no significant differences between the sex, age, and
basal Hb value between the groups using ACEI and ARB.
In addition, patients with severe heart failure were not
included in our study to avoid confusion in the results
because after starting RAAS blockers in patients with
heart failure, it has been reported that there is an increase
in Hb levels due to the improvement in heart failure and a
decrease in dilution due to congestion.
EPO resistance has been found to increase in patients
using ACEIs/ARBs, depending on the dose [14]. In
addition, in studies investigating the effects of RAAS
blockers on the treatment of secondary polycythemia, a
dose-related decrease in hematocrit was reported in the
first month of treatment [2,11]. In our study, the effect of
dose-related anemia was not compared for reasons such
as the absence of standard doses of ACEIs or ARBs and
the inability to adequately assess patient compliance due
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to the retrospective nature of the study. However, the
follow-up time for control Hb assessment was higher in
the ARB group. Although patient compliance is unknown,
a long follow-up period may indicate a high cumulative
dose. This may explain the more pronounced decrease in
Hb observed with ARBs in our study. In addition, there
may be different reasons for the effect of Hb reduction in
patients receiving ARBs, which may be the subject of other
studies.
The strengths of this study are that Hb levels of all
patients included in the study were within normal limits
and that parameters such as iron, vitamin B12, and folate
levels were evaluated before the patients were started on
RAAS blockers. Ferritin, iron/iron binding, vitamin B12,
and folate records of the patients at least 6 months before
starting the treatment with RAAS blockers were scanned
and only patients whose parameters were within the
normal range were included in the study. Therefore, only a
limited number of patients could be included in the study.
Our study has some limitations. The most important
one is the small number of patients included in the study.
The number of patients included in the study remained
low since only the patients who were retrospectively
determined to have met the inclusion criteria were included
in the study. The causal relationship between RAAS
blockers use and EPO level could not be investigated due
to the retrospective nature of the study, as EPO level is not
measured routinely. Lastly, there was no standardization
regarding the types and doses of ACEIs or ARBs used
by the patients included in the study, and the patient
compliance could not be fully addressed.
In conclusion, in this study, a significant decrease was
detected in the Hb levels measured in the first year following
the initial administration of ACEIs or ARBs to patients
with hypertension and/or diabetes but without significant
renal failure and anemia. This effect was more pronounced
in the group that has used ARBs. Although this group of
drugs have renoprotective and cardioprotective effects, it
may be appropriate to administer to patients with anemia,
considering the benefit-harm balance, since anemia may
worsen diabetic nephropathy and cardiovascular failure.
In addition, it would be more appropriate to evaluate Hb
levels in the first year after the first administration of RAAS
blockers, especially in patients with a tendency to anemia.
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